Compare Amgen, Inc. (AMGN) vs Linde PLC (LIN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Linde PLC — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while Linde PLC trades at $531.24 (market cap $244.95B). The key difference: Linde PLC is the larger of the two by market cap, and Amgen, Inc. pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| AMGN | LIN | |
|---|---|---|
Market Cap | $196.12B | $244.95B |
Sector | Health | Basic Materials |
52-Week High | $388.16 | $546.64 |
52-Week Low | $271.18 | $389.38 |
Enterprise Value | $241.41B | $267.30B |
Dividend Yield | 2.77% | 1.21% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Linde PLC (LIN) trades at $529.79, up 0.8% today, with strong analyst support (24 buy, 4 hold) and a consensus price target of $560. The stock shows consistent earnings beats, with Q1 2026 EPS of $4.33 exceeding estimates, and robust fundamentals including a 20.44% net margin and 18.49% ROE. Technical indicators are bullish overall, with the current price near resistance at $529.
Outlook remains positive due to steady revenue growth, high profitability, and shareholder returns via dividends. Risks include elevated valuation multiples (P/E 35.13) and rising debt-to-asset ratio. The stock offers a balanced opportunity for growth investors, supported by strong institutional sentiment and operational execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Linde PLC
Linde is the largest industrial gas supplier in the world, with operations in over 100 countries. The firm's main products are atmospheric gases (including oxygen, nitrogen, and argon) and process gases (including hydrogen, carbon dioxide, and helium), as well as equipment used in industrial gas production. Linde serves a wide variety of end markets, including chemicals, manufacturing, healthcare, and steelmaking. Linde generated approximately $31 billion in revenue and $5 billion in GAAP operating profit in 2021.
Read more on LIN →
